New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions

Podcast: JAMA Medical News · JAMA Network

Opublikowano: 2026-06-18

Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more. Related Content: A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026